The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Business Services/Equipment M&A

Construction M&A
   General Contractors & Builders M&A
Consumer Goods M&A
   Sporting Goods & Activities M&A
   Office Supplies M&A
   Food & Beverage M&A
   Beverages & Wineries M&A
   Cigarettes & Tobacco M&A
   Marijuana Stocks M&A
   Apparel Stores M&A
   Department Stores M&A
   Grocery & Drug Stores M&A
   Electronics Stores M&A
   Home Improvement Stores M&A
   Home Furnishing Stores M&A
   Auto Dealerships M&A
   Specialty Retail M&A
Consumer Services M&A
   Education & Training Services M&A
Energy M&A
   Oil & Gas Refining & Marketing M&A
   Oil & Gas Exploration & Production M&A
   Oil & Gas Equipment & Services M&A
Financial M&A
   Banking & Savings M&A
   Investment Brokerages M&A
   Investment Companies & Venture Capital M&A
   Asset Management M&A
   Credit Services & Lending M&A
   Life & Health Insurance M&A
   Insurance Brokers M&A
Healthcare M&A
   Drugs & Pharmaceuticals M&A
   Biotechnology M&A
   Diagnostics M&A
   Medical Instruments & Supplies M&A
   Hospital & Medical Practitioners M&A
Industrial M&A
   Chemicals M&A
   Specialty Chemicals M&A
   Defense M&A
   Aerospace & Defense M&A
   Construction Materials & Machinery M&A
   Industrial Machinery & Equipment M&A
Manufacturing M&A
   Home Furnishings & Furniture M&A
   Auto Manufacturers M&A
   Auto Parts M&A
   Textiles & Apparel M&A
Materials M&A
   Agricultural Chemicals M&A
   Rubber & Plastics M&A
   Paper & Forest Products M&A
   Packaging & Containers M&A
   Agriculture & Farm Products M&A
Media M&A
   Advertising M&A
   Television & Radio M&A
   Publishing & Printing M&A
Metals & Mining M&A
   Precious Metals M&A
   Non-Precious Metals & Non-Metallic Mining M&A
   Metals Fabrication & Products M&A
Real Estate M&A
   REITs M&A
Technology M&A
   Electronic Equipment & Products M&A
   3D Printing Stocks M&A
   Computers M&A
   Computer Peripherals M&A
   Application Software M&A
   Semiconductors M&A
   Information Technology Services M&A
Transportation M&A
   Air Services Other M&A
   Airlines M&A
   Trucking M&A
   Shipping M&A
   Railroads M&A
Travel & Entertainment M&A
   Hotels, Lodging, Restaurants & Travel M&A
   Entertainment M&A
Utilities M&A
   Waste Management M&A
   Communications Services M&A
   Electric Utilities M&A
   Gas Utilities M&A
   Water Utilities M&A
Mega Mergers
Daily M&A
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
Stock Buybacks
IPOs
Secondary Offerings
Top 20 Large Caps
Top 20 Biggest ETFs
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Articles
CAGR Calculator
Dunnan On Dollars
10 Pot Stocks
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement

Slideshow Mergers & Acquisitions

By The Online Investor Staff, updated Thu., Apr. 25, 5:54 AM

This Slide: #73 of 100

Slide #73. Eliem Therapeutics, Inc. — Tenet Medicines

Acquirer: Eliem Therapeutics, Inc. (NASDAQ:ELYM)
Acquiree: Tenet Medicines
Details: Eliem Therapeutics, Inc. (Nasdaq: ELYM) ("Eliem") and Tenet Medicines, Inc. ("Tenet"), a development-stage private biotechnology company, today announced that the companies have entered into a definitive acquisition agreement whereby Eliem has agreed to acquire Tenet. The combined company plans to focus on advancing TNT119, a potentially best-in class anti-CD19 antibody, designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy.

Eliem Therapeutics is a clinical-stage biotechnology company focused on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Co. is developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with therapeutic potential to deliver therapeutics for patients with these disorders. Co.'s two clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a palmitoylethanolamide prodrug for the treatment of diabetic peripheral neuropathic pain and lumbosacral radicular pain, commonly referred to as sciatica.

Open the ELYM Page at The Online Investor »

ELYM — Key Stats (updated 18 hours, 35 minutes ago)
Company Name:  Eliem Therapeutics Inc
Website:  www.eliemtx.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding ELYM:  3
Total Market Value Held by ETFs:  $1.24M
Total Market Capitalization:  $107.00M
% of Market Cap. Held by ETFs:  1.16%
 

Open the ELYM Page at The Online Investor (in a new window) »
April 25, 2024  •  5:54 AM Eastern
ELYM — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree ELYM Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Avg. Broker Rec.

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Mergers & Acquisitions | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.